Soleus Capital Management’s AngioDynamics ANGO Stock Holding History

Soleus Capital Management’s Portfolio ANGO Stock Details ANGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-768,500	Closed	-$8.02M	–	95
2023 Q2	$8.02M	Buy	768,500 +543,500	+242%	+$5.23M	0.89%	35
2023 Q1	$2.33M	Buy	+225,000	New	+$2.88M	0.24%	63
2022 Q3	–	Sell	-670,000	Closed	-$13M	–	77
2022 Q2	$13M	Sell	670,000 -356,450	-35%	-$7.3M	2.02%	15
2022 Q1	$22.1M	Buy	1,026,450 +511,000	+99%	+$11.6M	2.85%	6
2021 Q4	$14.2M	Buy	515,450 +272,925	+113%	+$7.53M	1.42%	25
2021 Q3	$6.29M	Buy	+242,525	New	+$6.49M	0.98%	31

Other funds holding ANGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Soleus Capital Management's ANGO Position: Q3 2023 in Review

Soleus Capital Management sold out of AngioDynamics (ANGO) in Q3 2023, closing a stake of 768,500 shares — an estimated $8.02M sold.

Soleus Capital Management first reported a position in ANGO in Q3 2021 and held it in 6 quarters. The position peaked at $22.1M in Q1 2022. 154 funds tracked by Wall St. Rank hold ANGO as of Q3 2023.

Soleus Capital Management reported no remaining AngioDynamics position as of Q3 2023 after selling out during the quarter.
Soleus Capital Management sold 768,500 AngioDynamics shares in Q3 2023, an estimated $8.02M.
Soleus Capital Management first reported a position in AngioDynamics in Q3 2021 and held it in 6 quarters.
Soleus Capital Management's AngioDynamics position peaked at $22.1M in Q1 2022.
154 funds tracked by Wall St. Rank held AngioDynamics as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.